JP2015504071A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015504071A5 JP2015504071A5 JP2014551304A JP2014551304A JP2015504071A5 JP 2015504071 A5 JP2015504071 A5 JP 2015504071A5 JP 2014551304 A JP2014551304 A JP 2014551304A JP 2014551304 A JP2014551304 A JP 2014551304A JP 2015504071 A5 JP2015504071 A5 JP 2015504071A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- composition
- group
- cell
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 11
- 239000013598 vector Substances 0.000 claims description 10
- 210000004027 cell Anatomy 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 5
- 102100034256 Mucin-1 Human genes 0.000 claims description 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 210000004443 dendritic cell Anatomy 0.000 claims description 4
- 102000014150 Interferons Human genes 0.000 claims description 3
- 108010050904 Interferons Proteins 0.000 claims description 3
- 229940079322 interferon Drugs 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 108010071942 Colony-Stimulating Factors Proteins 0.000 claims description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 2
- 230000028993 immune response Effects 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 108010065805 Interleukin-12 Proteins 0.000 claims 3
- 230000003308 immunostimulating effect Effects 0.000 claims 3
- 230000001105 regulatory effect Effects 0.000 claims 3
- 229920001661 Chitosan Polymers 0.000 claims 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 2
- 108010063738 Interleukins Proteins 0.000 claims 2
- 102000015696 Interleukins Human genes 0.000 claims 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000013612 plasmid Substances 0.000 claims 2
- 102000003390 tumor necrosis factor Human genes 0.000 claims 2
- 241000710929 Alphavirus Species 0.000 claims 1
- 241000700663 Avipoxvirus Species 0.000 claims 1
- 108010084313 CD58 Antigens Proteins 0.000 claims 1
- 102100025221 CD70 antigen Human genes 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 241000178270 Canarypox virus Species 0.000 claims 1
- 241000700664 Capripoxvirus Species 0.000 claims 1
- 102000001327 Chemokine CCL5 Human genes 0.000 claims 1
- 108010055166 Chemokine CCL5 Proteins 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 241000991587 Enterovirus C Species 0.000 claims 1
- 208000000666 Fowlpox Diseases 0.000 claims 1
- 241000700662 Fowlpox virus Species 0.000 claims 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims 1
- 101000764263 Homo sapiens Tumor necrosis factor ligand superfamily member 4 Proteins 0.000 claims 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 241000700629 Orthopoxvirus Species 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- 241000710960 Sindbis virus Species 0.000 claims 1
- 241000700568 Suipoxvirus Species 0.000 claims 1
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 claims 1
- 241000700618 Vaccinia virus Species 0.000 claims 1
- 206010046865 Vaccinia virus infection Diseases 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 229940037003 alum Drugs 0.000 claims 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 1
- 229910052782 aluminium Inorganic materials 0.000 claims 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims 1
- -1 antibiotic Substances 0.000 claims 1
- 229940121375 antifungal agent Drugs 0.000 claims 1
- 239000003429 antifungal agent Substances 0.000 claims 1
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 239000001506 calcium phosphate Substances 0.000 claims 1
- 229910000389 calcium phosphate Inorganic materials 0.000 claims 1
- 235000011010 calcium phosphates Nutrition 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000003714 granulocyte Anatomy 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 210000001616 monocyte Anatomy 0.000 claims 1
- 239000000377 silicon dioxide Substances 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241000701447 unidentified baculovirus Species 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 241001430294 unidentified retrovirus Species 0.000 claims 1
- 208000007089 vaccinia Diseases 0.000 claims 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 102100020873 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261582723P | 2012-01-03 | 2012-01-03 | |
| US61/582,723 | 2012-01-03 | ||
| PCT/US2013/020058 WO2013103658A1 (en) | 2012-01-03 | 2013-01-03 | Native and agonist ctl epitopes of the muc1 tumor antigen |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015504071A JP2015504071A (ja) | 2015-02-05 |
| JP2015504071A5 true JP2015504071A5 (enExample) | 2016-02-25 |
| JP6523685B2 JP6523685B2 (ja) | 2019-06-05 |
Family
ID=47559756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014551304A Active JP6523685B2 (ja) | 2012-01-03 | 2013-01-03 | Ｍｕｃ１腫瘍抗原のネイティブ及びアゴニストｃｔｌエピトープ |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10138271B2 (enExample) |
| EP (1) | EP2800762B1 (enExample) |
| JP (1) | JP6523685B2 (enExample) |
| AU (1) | AU2013206896B2 (enExample) |
| CA (1) | CA2860599C (enExample) |
| DK (1) | DK2800762T3 (enExample) |
| ES (1) | ES2664325T3 (enExample) |
| WO (1) | WO2013103658A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9090673B2 (en) * | 2003-12-12 | 2015-07-28 | City Of Hope | Synthetic conjugate of CpG DNA and T-help/CTL peptide |
| US8871247B2 (en) | 2007-02-19 | 2014-10-28 | Marine Polymer Technologies, Inc. | Hemostatic compositions and therapeutic regimens |
| CA3205348A1 (en) * | 2013-10-23 | 2015-04-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use |
| EP3349785A1 (en) * | 2015-09-16 | 2018-07-25 | Herlev Hospital | Vaccine compositions comprising c-c motif chemokine 22 (ccl22) or fragments thereof |
| AU2017336269B2 (en) | 2016-09-28 | 2022-06-16 | Bavarian Nordic A/S | Compositions and methods for enhancing the stability of transgenes in poxviruses |
| EP3542814B1 (en) * | 2018-03-21 | 2022-08-24 | Universitätsmedizin der Johannes Gutenberg-Universität Mainz | Novel peptide-based compounds for use in the prevention, treatment and/or detection of cancer |
| IL281988B2 (en) | 2018-10-05 | 2025-03-01 | Bavarian Nordic As | Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an immune checkpoint antagonist or agonist |
| WO2020104531A1 (en) | 2018-11-20 | 2020-05-28 | Bavarian Nordic A/S | Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l |
| MX2022005664A (es) | 2019-11-20 | 2022-09-07 | Bavarian Nordic As | Virus de vaccinia ankara modificados (mva) recombinantes para administración intratumoral y/o intravenosa para tratamiento de cáncer. |
| EP4452305A1 (en) | 2021-12-23 | 2024-10-30 | Bavarian Nordic A/S | Recombinant mva viruses for intraperitoneal administration for treating cancer |
| JP2025502463A (ja) * | 2022-01-24 | 2025-01-24 | サイロン セラピューティクス カンパニー リミテッド | Ｍｕｃ－１に特異的に結合する抗体およびその用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4885172A (en) | 1985-06-26 | 1989-12-05 | The Liposome Company, Inc. | Composition for targeting, storing and loading of liposomes |
| US5059421A (en) | 1985-07-26 | 1991-10-22 | The Liposome Company, Inc. | Preparation of targeted liposome systems of a defined size distribution |
| IE912535A1 (en) | 1990-07-27 | 1992-01-29 | Res Dev Foundation | Liposomes that Provide Thymic Dependent Help to Weak Vaccine¹Antigens |
| US5744144A (en) | 1993-07-30 | 1998-04-28 | University Of Pittsburgh University Patent Committee Policy And Procedures | Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof |
| US6548643B1 (en) | 1994-11-16 | 2003-04-15 | Austin Research Institute | Antigen carbohydrate compounds and their use in immunotherapy |
| US5643599A (en) | 1995-06-07 | 1997-07-01 | President And Fellows Of Harvard College | Intracellular delivery of macromolecules |
| CA2289742C (en) | 1997-05-08 | 2013-07-16 | Biomira Inc. | Method for generating activated t-cells and antigen-pulsed antigen-presenting cells |
| US20090004212A1 (en) * | 1997-12-30 | 2009-01-01 | Franz-Georg Hanisch | Tumour vaccines for MUC1-positive carcinomas |
| IL125608A0 (en) | 1998-07-30 | 1999-03-12 | Yeda Res & Dev | Tumor associated antigen peptides and use of same as anti-tumor vaccines |
| ATE338121T1 (de) * | 1999-09-08 | 2006-09-15 | Transgene Sa | Von muc-1 abgeleitete peptide |
| EP1601333B1 (en) | 2003-02-20 | 2013-01-23 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services | Novel insertion sites in pox vectors |
| US7696306B2 (en) | 2003-07-11 | 2010-04-13 | Board of Agents of the University of Nebraska | Compositions and methods for preventing or treating cancer |
| AU2004289368B2 (en) | 2003-11-12 | 2010-08-26 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Custom vectors for treating and preventing pancreatic cancer |
| AU2004289340B2 (en) | 2003-11-12 | 2010-11-11 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | System for treating and preventing breast cancer |
| WO2005058937A2 (en) * | 2003-12-12 | 2005-06-30 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A human cytotoxic t-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of muc-1 |
| JP2009544291A (ja) * | 2006-07-25 | 2009-12-17 | フォージー ヴァクシンズ ピーティーワイ エルーティーディー | ムチン１（ｍｕｃ１）ｔ細胞エピトープ由来ペプチド含有癌ワクチン |
| US20110318380A1 (en) * | 2008-10-01 | 2011-12-29 | Dako Denmark A/S | MHC Multimers in Cancer Vaccines and Immune Monitoring |
| EP2744918A4 (en) * | 2011-08-17 | 2015-06-10 | Globeimmune Inc | IMMUNOTHERAPEUTIC YEAST MUC1 COMPOSITIONS AND USES THEREOF |
-
2013
- 2013-01-03 ES ES13700352.1T patent/ES2664325T3/es active Active
- 2013-01-03 CA CA2860599A patent/CA2860599C/en active Active
- 2013-01-03 DK DK13700352.1T patent/DK2800762T3/en active
- 2013-01-03 AU AU2013206896A patent/AU2013206896B2/en active Active
- 2013-01-03 WO PCT/US2013/020058 patent/WO2013103658A1/en not_active Ceased
- 2013-01-03 JP JP2014551304A patent/JP6523685B2/ja active Active
- 2013-01-03 EP EP13700352.1A patent/EP2800762B1/en active Active
- 2013-01-03 US US14/370,595 patent/US10138271B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015504071A5 (enExample) | ||
| CN103751771B (zh) | 免疫诱导剂 | |
| KR102874251B1 (ko) | 신생항원 및 이의 용도 | |
| CN1805758B (zh) | 核酸和细胞疫苗的组分 | |
| JP6558699B2 (ja) | 抗原提示を促進するエピトープ間配列を含むｔ細胞誘導ワクチン | |
| RU2008114624A (ru) | Композиции и способы для лечения опухолей, презентирующих антигены сурвивина | |
| KR20210040355A (ko) | 네오항원 및 이의 용도 | |
| CN106029699A (zh) | Wt1抗原性多肽和含有该多肽的抗肿瘤剂 | |
| US20230190899A1 (en) | Immune inducer | |
| CN120983614A (zh) | 用于刺激i型干扰素基因的包括阳离子脂质的方法和组合物 | |
| KR20220110181A (ko) | 다중-도메인 단백질 백신 | |
| Lauterbach et al. | Genetic adjuvantation of recombinant MVA with CD40L potentiates CD8 T cell mediated immunity | |
| US20220331417A1 (en) | Modified vesicular stomatitis virus glycoprotein and uses thereof for the treatment of brain tumors | |
| JP2012504948A (ja) | ヒト上皮細胞の免疫賦活活性の増強剤としてのオンコスタチンｍ | |
| JP3876162B2 (ja) | 肝細胞癌の治療のための方法及び組成物 | |
| EP1074267B1 (en) | Induction of antigen-specific T cells by interferon | |
| CN108697757B (zh) | 免疫诱导剂 | |
| RU2733841C2 (ru) | Иммуноиндуцирующее средство | |
| CA2993427C (en) | Immune inducer | |
| CN107530411B (zh) | 免疫诱导剂 |